Skip to content

Novavax Inc (NVAX) stock: revenue, earnings & dividend

Novavax Inc (NVAX, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener NVAX ยท Nasdaq Pharma & Biotech MD-

Key figures

Fiscal year
2025
Revenue
1.12 bn $
Revenue growth
64.7 %
Revenue growth 5y (p.a.)
18.8 %
Net income
440 m $
Net margin
39.2 %
Operating margin
40.3 %
Earnings per share (diluted)
2.58 $
Dividend per share
โ€“
Payout ratio
โ€“
Consecutive dividend years
โ€“
Consecutive dividend raises
โ€“
Dividend growth 5y (p.a.)
โ€“
Total assets
1.18 bn $
Equity
-127.75 m $
Equity ratio
-10.9 %
Return on equity
โ€“
Cash
241 m $
Operating cash flow
-244.64 m $
Free cash flow
โ€“
Shares outstanding
165,009,009

History

Revenue by fiscal year

2016 15.4 m $
2017 31.2 m $
2018 34.3 m $
2019 18.7 m $
2020 476 m $
2021 1.15 bn $
2022 1.98 bn $
2023 984 m $
2024 682 m $
2025 1.12 bn $

Net income by fiscal year

2016 -279.97 m $
2017 -183.77 m $
2018 -184.75 m $
2019 -132.69 m $
2020 -418.26 m $
2021 -1.74 bn $
2022 -657.94 m $
2023 -545.06 m $
2024 -187.5 m $
2025 440 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20251.12 bn $440 m $2.58 $โ€“-244.64 m $
2024682 m $-187.5 m $-1.23 $โ€“-87.26 m $
2023984 m $-545.06 m $-5.41 $โ€“-713.97 m $
20221.98 bn $-657.94 m $-8.42 $โ€“-415.94 m $
20211.15 bn $-1.74 bn $-23.44 $โ€“323 m $
2020476 m $-418.26 m $-7.27 $โ€“-42.54 m $
201918.7 m $-132.69 m $-5.51 $โ€“-136.62 m $
201834.3 m $-184.75 m $โ€“โ€“-184.83 m $
201731.2 m $-183.77 m $โ€“โ€“-144.48 m $
201615.4 m $-279.97 m $โ€“โ€“-258.77 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)